TherapeuticsMD, Inc. (NASDAQ: TXMD) Stock Competitors & Peer Comparison
See TXMD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TXMD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TXMD | $2.24 | -0.88% | 25.9M | 114.11 | $0.02 | N/A |
| TAK | $18.71 | +1.52% | 59.5B | 13.45 | $1.39 | +3.37% |
| HLN | $9.86 | -0.50% | 43.4B | 18.39 | $0.54 | +2.01% |
| TEVA | $36.62 | -2.32% | 42.6B | 12.50 | $2.93 | N/A |
| ZTS | $76.29 | +0.16% | 32B | 11.59 | $6.58 | +2.73% |
| VTRS | $16.94 | -0.88% | 19.7B | 6.72 | $2.52 | +2.83% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.42 | -1.05% | 12.2B | 23.03 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.03 | -1.11% | 10B | 19.73 | $0.61 | +0.70% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
TXMD vs TAK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TAK has a market cap of 59.5B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TAK trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TAK's P/E ratio is 13.45. In terms of profitability, TXMD's ROE is -0.01%, compared to TAK's ROE of +0.02%. Regarding short-term risk, TXMD is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TAK's competition here
Haleon plc (NYSE: HLN)
TXMD vs HLN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while HLN trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas HLN's P/E ratio is 18.39. In terms of profitability, TXMD's ROE is -0.01%, compared to HLN's ROE of +0.17%. Regarding short-term risk, TXMD is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
TXMD vs TEVA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TEVA has a market cap of 42.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TEVA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TEVA's P/E ratio is 12.50. In terms of profitability, TXMD's ROE is -0.01%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TXMD is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
TXMD vs ZTS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ZTS has a market cap of 32B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ZTS trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ZTS's P/E ratio is 11.59. In terms of profitability, TXMD's ROE is -0.01%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, TXMD is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
TXMD vs VTRS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while VTRS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas VTRS's P/E ratio is 6.72. In terms of profitability, TXMD's ROE is -0.01%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TXMD is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TXMD vs ITCI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TXMD's ROE is -0.01%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TXMD vs ELAN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ELAN trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ELAN's P/E ratio is 23.03. In terms of profitability, TXMD's ROE is -0.01%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
TXMD vs CTLT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TXMD's ROE is -0.01%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TXMD is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TXMD vs RDY Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, RDY has a market cap of 10B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while RDY trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas RDY's P/E ratio is 19.73. In terms of profitability, TXMD's ROE is -0.01%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TXMD is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
TXMD vs ALKS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ALKS trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ALKS's P/E ratio is 49.35. In terms of profitability, TXMD's ROE is -0.01%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TXMD is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TXMD vs LNTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while LNTH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas LNTH's P/E ratio is 16.97. In terms of profitability, TXMD's ROE is -0.01%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TXMD is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TXMD vs AMRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AMRX trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AMRX's P/E ratio is 19.86. In terms of profitability, TXMD's ROE is -0.01%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TXMD is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TXMD vs INDV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while INDV trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas INDV's P/E ratio is 9.54. In terms of profitability, TXMD's ROE is -0.01%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TXMD is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TXMD vs RGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas RGC's P/E ratio is -456.34. In terms of profitability, TXMD's ROE is -0.01%, compared to RGC's ROE of -2.32%. Regarding short-term risk, TXMD is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
TXMD vs ALVOW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ALVOW's P/E ratio is 46.65. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TXMD is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
TXMD vs SUPN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SUPN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SUPN's P/E ratio is 14.38. In terms of profitability, TXMD's ROE is -0.01%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TXMD is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TXMD vs BHC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas BHC's P/E ratio is 1.73. In terms of profitability, TXMD's ROE is -0.01%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TXMD is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TXMD vs HCM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while HCM trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas HCM's P/E ratio is 5.29. In terms of profitability, TXMD's ROE is -0.01%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TXMD is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TXMD vs DCPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TXMD's ROE is -0.01%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TXMD is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TXMD vs AVDL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TXMD's ROE is -0.01%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, TXMD is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
TXMD vs TRLV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TRLV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TRLV's P/E ratio is -4.88. In terms of profitability, TXMD's ROE is -0.01%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, TXMD is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
TXMD vs PRGO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PRGO trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PRGO's P/E ratio is 5.71. In terms of profitability, TXMD's ROE is -0.01%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TXMD is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
TXMD vs EMBCV Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TXMD's ROE is -0.01%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TXMD is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TXMD vs DVAX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TXMD's ROE is -0.01%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, TXMD is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
TXMD vs ALVO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ALVO trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ALVO's P/E ratio is -15.82. In terms of profitability, TXMD's ROE is -0.01%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TXMD is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TXMD vs ETON Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ETON trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ETON's P/E ratio is 130.22. In terms of profitability, TXMD's ROE is -0.01%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TXMD is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TXMD vs ANIP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ANIP trades at $71.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ANIP's P/E ratio is 8.76. In terms of profitability, TXMD's ROE is -0.01%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TXMD is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TXMD vs TARO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TARO's P/E ratio is 30.05. In terms of profitability, TXMD's ROE is -0.01%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TXMD is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TXMD vs PAHC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PAHC trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PAHC's P/E ratio is 13.17. In terms of profitability, TXMD's ROE is -0.01%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TXMD is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TXMD vs HROW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while HROW trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas HROW's P/E ratio is -38.65. In terms of profitability, TXMD's ROE is -0.01%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TXMD is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
TXMD vs CRON Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CRON's P/E ratio is 30.96. In terms of profitability, TXMD's ROE is -0.01%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TXMD is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TXMD vs AMPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AMPH trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AMPH's P/E ratio is 8.14. In terms of profitability, TXMD's ROE is -0.01%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TXMD is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TXMD vs PCRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PCRX trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PCRX's P/E ratio is 10.23. In terms of profitability, TXMD's ROE is -0.01%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TXMD is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TXMD vs PETQ Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TXMD's ROE is -0.01%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TXMD is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TXMD vs COLL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, COLL has a market cap of 768.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while COLL trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas COLL's P/E ratio is 2.97. In terms of profitability, TXMD's ROE is -0.01%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TXMD is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TXMD vs IRWD Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas IRWD's P/E ratio is 5.50. In terms of profitability, TXMD's ROE is -0.01%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TXMD is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
TXMD vs EVO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, EVO has a market cap of 675M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas EVO's P/E ratio is -2.68. In terms of profitability, TXMD's ROE is -0.01%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TXMD is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TXMD vs AQST Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AQST has a market cap of 671.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AQST trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AQST's P/E ratio is -8.23. In terms of profitability, TXMD's ROE is -0.01%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TXMD is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AQST's competition here
Glass House Brands Inc (NYSE: GLAS)
TXMD vs GLAS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, GLAS has a market cap of 662.8M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while GLAS trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas GLAS's P/E ratio is -15.30. In terms of profitability, TXMD's ROE is -0.01%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TXMD is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
TXMD vs EOLS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, EOLS has a market cap of 596M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while EOLS trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas EOLS's P/E ratio is -28.66. In terms of profitability, TXMD's ROE is -0.01%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TXMD is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TXMD vs BDSI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TXMD's ROE is -0.01%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TXMD is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TXMD vs TLRY Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TLRY has a market cap of 506.6M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TLRY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TLRY's P/E ratio is -4.18. In terms of profitability, TXMD's ROE is -0.01%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, TXMD is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
TXMD vs KMDA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, KMDA has a market cap of 477.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas KMDA's P/E ratio is 21.76. In terms of profitability, TXMD's ROE is -0.01%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TXMD is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TXMD vs CGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CGC has a market cap of 410.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CGC's P/E ratio is -0.59. In terms of profitability, TXMD's ROE is -0.01%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TXMD is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TXMD vs TKNO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TKNO has a market cap of 388.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TKNO trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TKNO's P/E ratio is -23.35. In terms of profitability, TXMD's ROE is -0.01%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TXMD is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
TXMD vs EBS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, EBS has a market cap of 322M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while EBS trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas EBS's P/E ratio is 4.33. In terms of profitability, TXMD's ROE is -0.01%, compared to EBS's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TXMD vs ALIM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TXMD's ROE is -0.01%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TXMD is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
TXMD vs LNDC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TXMD is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check LNDC's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TXMD vs CRDL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CRDL has a market cap of 249M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CRDL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CRDL's P/E ratio is -8.61. In terms of profitability, TXMD's ROE is -0.01%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TXMD is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CRDL's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TXMD vs ACB Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ACB has a market cap of 241M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ACB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ACB's P/E ratio is -7.94. In terms of profitability, TXMD's ROE is -0.01%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TXMD is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TXMD vs SIGA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SIGA has a market cap of 231.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SIGA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SIGA's P/E ratio is 11.96. In terms of profitability, TXMD's ROE is -0.01%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TXMD is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
TXMD vs TYHT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TXMD's ROE is -0.01%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TXMD is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
TXMD vs DERM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, DERM has a market cap of 217.4M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while DERM trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas DERM's P/E ratio is -21.35. In terms of profitability, TXMD's ROE is -0.01%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TXMD is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TXMD vs ORGO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ORGO has a market cap of 211M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ORGO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ORGO's P/E ratio is 54.67. In terms of profitability, TXMD's ROE is -0.01%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TXMD is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TXMD vs REPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas REPH's P/E ratio is -8.04. In terms of profitability, TXMD's ROE is -0.01%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TXMD is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
TXMD vs OGI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, OGI has a market cap of 164.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while OGI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas OGI's P/E ratio is 2.63. In terms of profitability, TXMD's ROE is -0.01%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TXMD is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TXMD vs LFCR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, LFCR has a market cap of 163.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while LFCR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas LFCR's P/E ratio is -4.07. In terms of profitability, TXMD's ROE is -0.01%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, TXMD is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TXMD vs THTX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas THTX's P/E ratio is -28.83. In terms of profitability, TXMD's ROE is -0.01%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TXMD is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TXMD vs ASRT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TXMD's ROE is -0.01%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TXMD is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TXMD vs SCTL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TXMD's ROE is -0.01%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TXMD is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
TXMD vs BGM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, BGM has a market cap of 107.8M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas BGM's P/E ratio is -0.98. In terms of profitability, TXMD's ROE is -0.01%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TXMD is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
TXMD vs PROC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PROC's P/E ratio is 1.53. In terms of profitability, TXMD's ROE is -0.01%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TXMD is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TXMD vs CPIX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CPIX's P/E ratio is -16.87. In terms of profitability, TXMD's ROE is -0.01%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TXMD is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TXMD vs OPTN Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TXMD is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TXMD vs ZOM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TXMD's ROE is -0.01%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TXMD is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
TXMD vs GRVI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TXMD's ROE is -0.01%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, TXMD is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TXMD vs ZYBT Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, TXMD is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TXMD vs ZYNE Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TXMD's ROE is -0.01%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TXMD is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TXMD vs SSIC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TXMD's ROE is -0.01%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TXMD is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
TXMD vs INCR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while INCR trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas INCR's P/E ratio is -12.23. In terms of profitability, TXMD's ROE is -0.01%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TXMD is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
TXMD vs TLPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas TLPH's P/E ratio is -3.87. In terms of profitability, TXMD's ROE is -0.01%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TXMD is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TXMD vs VLNS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TXMD's ROE is -0.01%, compared to VLNS's ROE of N/A. Regarding short-term risk, TXMD is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
TXMD vs DRRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TXMD's ROE is -0.01%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, TXMD is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TXMD vs JUPW Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TXMD's ROE is -0.01%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TXMD is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TXMD vs QLI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas QLI's P/E ratio is -4.92. In terms of profitability, TXMD's ROE is -0.01%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TXMD is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TXMD vs CPHI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CPHI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CPHI's P/E ratio is -1.97. In terms of profitability, TXMD's ROE is -0.01%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TXMD is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TXMD vs RMTI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while RMTI trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas RMTI's P/E ratio is -5.96. In terms of profitability, TXMD's ROE is -0.01%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TXMD is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
TXMD vs HEXO Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TXMD's ROE is -0.01%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TXMD is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check HEXO's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TXMD vs AYTU Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AYTU's P/E ratio is -1.19. In terms of profitability, TXMD's ROE is -0.01%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, TXMD is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TXMD vs CYTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TXMD's ROE is -0.01%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TXMD is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TXMD vs EVOK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TXMD's ROE is -0.01%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, TXMD is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TXMD vs OPTH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, OPTH has a market cap of 15.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while OPTH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas OPTH's P/E ratio is -17.24. In terms of profitability, TXMD's ROE is -0.01%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TXMD is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TXMD vs ACRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TXMD's ROE is -0.01%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TXMD is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
TXMD vs CABR Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, CABR has a market cap of 11.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while CABR trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas CABR's P/E ratio is -2.29. In terms of profitability, TXMD's ROE is -0.01%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TXMD is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TXMD vs AGRX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TXMD's ROE is -0.01%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TXMD is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TXMD vs NLTX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TXMD's ROE is -0.01%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TXMD is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check NLTX's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TXMD vs GELS Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, GELS has a market cap of 7.9M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while GELS trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas GELS's P/E ratio is -1.72. In terms of profitability, TXMD's ROE is -0.01%, compared to GELS's ROE of -0.25%. Regarding short-term risk, TXMD is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check GELS's competition here
Lannett Company, Inc. (NYSE: LCI)
TXMD vs LCI Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas LCI's P/E ratio is -0.04. In terms of profitability, TXMD's ROE is -0.01%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TXMD is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TXMD vs ADMP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TXMD's ROE is -0.01%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TXMD is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
TXMD vs YCBD Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, YCBD has a market cap of 5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas YCBD's P/E ratio is -1.17. In terms of profitability, TXMD's ROE is -0.01%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TXMD is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
TXMD vs MNK Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas MNK's P/E ratio is -0.44. In terms of profitability, TXMD's ROE is -0.01%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TXMD is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TXMD vs FLGC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TXMD's ROE is -0.01%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TXMD is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
TXMD vs UPC Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while UPC trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas UPC's P/E ratio is -0.54. In terms of profitability, TXMD's ROE is -0.01%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TXMD is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
TXMD vs SBFM Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SBFM has a market cap of 2.6M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SBFM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SBFM's P/E ratio is -0.18. In terms of profitability, TXMD's ROE is -0.01%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, TXMD is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TXMD vs PLXP Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TXMD's ROE is -0.01%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TXMD is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
TXMD vs ATNX Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TXMD's ROE is -0.01%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TXMD is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
TXMD vs RDHL Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas RDHL's P/E ratio is 0.14. In terms of profitability, TXMD's ROE is -0.01%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, TXMD is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TXMD vs SNOA Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SNOA's P/E ratio is -1.12. In terms of profitability, TXMD's ROE is -0.01%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TXMD is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for TXMD.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TXMD vs SHPH Comparison September 2026
TherapeuticsMD, Inc. (NASDAQ: TXMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TXMD stands at 25.9M. In comparison, SHPH has a market cap of 2M. Regarding current trading prices, TXMD is priced at $2.24 on the NASDAQ, while SHPH trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TXMD currently has a P/E ratio of 114.11, whereas SHPH's P/E ratio is -0.16. In terms of profitability, TXMD's ROE is -0.01%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, TXMD is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TXMD.Check SHPH's competition here